Elbow Lesion MarketSize and Trends

Market Trends

Increasing geriatric population highly prone to bone injury and rising number of sports related injuries driving growth of the elbow lesion market

Rise in prevalence of elbow tendon, increasing incidence of elbow joint pain, and growth in healthcare investment are factors driving growth of the global market for elbow lesion. According to the National Institute for Health and Care Excellence (NICE) tennis elbow was prevalent in 1%-3% of UK population in 2012. It has been observed that people above 60 years are more afflicted with elbow pain. Therefore, rapidly growing geriatric population and increasing incidence of arm fracture due to accidents are expected to drive growth of the elbow lesion market in the near future.

Platelet-rich plasma – An effective antidote for tennis elbow

The elbow lesion market is classified on the basis of treatment methods into surgical and non-surgical therapies. Arthroscopic surgery and open surgery are types of surgical therapies performed. Non-surgical therapies comprise drugs and physical therapy.

Various non-steroidal anti-inflammatory drugs (NSAIDS) such as ibuprofen, aspirin, and cortisone are administered to control pain. Other drugs used for treatment of elbow pain include botulinum toxin and hyaluronate propelling growth of the elbow lesion market. Platelet-rich plasma (PRP), a novel technique, is being preferred for treatment of tennis elbow. It involves taking a blood sample from the patient, which is then treated to increase the number of platelets compared with other cells in the sample. Physical therapies such as muscle stimulation and ice massage are used to expedite the healing process.